BTIG Research Has Lowered Expectations for Hims & Hers Health (NYSE:HIMS) Stock Price

Hims & Hers Health (NYSE:HIMS) had its price target decreased by analysts at BTIG Research from $85.00 to $60.00 in a research report issued on Monday, MarketBeat reports. The firm currently has a “buy” rating on the stock. BTIG Research’s price objective indicates a potential upside of 135.00% from the stock’s current price.

Several other research firms have also recently commented on HIMS. Evercore ISI assumed coverage on Hims & Hers Health in a research report on Monday, January 12th. They issued an “in-line” rating and a $33.00 target price on the stock. Leerink Partners upgraded shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, December 4th. Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Barclays started coverage on shares of Hims & Hers Health in a research note on Monday, December 8th. They set an “overweight” rating and a $48.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $42.62.

Hims & Hers Health Stock Down 3.4%

HIMS stock opened at $25.53 on Monday. The stock has a market cap of $5.81 billion, a PE ratio of 47.28, a price-to-earnings-growth ratio of 4.35 and a beta of 2.43. The firm’s 50-day simple moving average is $33.88 and its 200 day simple moving average is $43.92. Hims & Hers Health has a fifty-two week low of $23.97 and a fifty-two week high of $72.98. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. During the same period in the previous year, the firm earned $0.32 earnings per share. The company’s revenue for the quarter was up 49.2% on a year-over-year basis. As a group, sell-side analysts predict that Hims & Hers Health will post 0.29 EPS for the current year.

Hims & Hers Health declared that its Board of Directors has initiated a stock buyback program on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 3% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling at Hims & Hers Health

In related news, COO Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $504,762.50. Following the transaction, the chief operating officer directly owned 305,161 shares in the company, valued at $11,202,460.31. The trade was a 4.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Oluyemi Okupe sold 9,067 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total value of $275,092.78. Following the sale, the chief financial officer directly owned 91,617 shares in the company, valued at $2,779,659.78. This trade represents a 9.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 131,974 shares of company stock valued at $4,763,800. Corporate insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently bought and sold shares of the stock. Maxi Investments CY Ltd purchased a new stake in Hims & Hers Health during the fourth quarter valued at about $3,253,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Hims & Hers Health during the fourth quarter valued at approximately $442,000. RFG Advisory LLC lifted its position in shares of Hims & Hers Health by 371.7% in the 4th quarter. RFG Advisory LLC now owns 79,081 shares of the company’s stock valued at $2,568,000 after acquiring an additional 62,316 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in shares of Hims & Hers Health by 16.7% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 38,766 shares of the company’s stock valued at $1,295,000 after acquiring an additional 5,541 shares in the last quarter. Finally, Strs Ohio boosted its stake in Hims & Hers Health by 5.9% in the 4th quarter. Strs Ohio now owns 37,800 shares of the company’s stock worth $1,227,000 after purchasing an additional 2,100 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.